Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...
Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 ...
A Comprehensive Guide to the Fetal Bovine Serum MarketThe biotechnology and pharmaceutical industries are currently ...
Survey of 800+ HCPs Finds Menopause Care is the #1 Area Where Providers Expect the Greatest Improvement in the Next 5 ...
The Assistive Technology Market refers to the global industry focused on designing, manufacturing, and distributing devices, ...
New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various ...
OverviewThe Global Medical Holographic Imaging Market is valued at USD 2.2 Billion in 2024 and is projected to reach a value ...
The medical landscape undergoes a rapid transformation as precision becomes the standard of care. At the heart of this ...
A SmartSense survey of 150 U.S.-based hospital CFOs finds 94% of respondents reporting unexpected expenses related to ...
Rossi Brings Decades of Leadership as Convergent Advances its Alpha-based Radioantibody for Prostate Cancer to Late-Stage ...
Clinical research organization uses AI agent-driven knowledge platform built on a unified contextual data layer to identify higher-performing trial sites faster and minimize inclusion of costly ...
March 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results